Diadema Partners’s ARS Pharmaceuticals SPRY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-4,860
Closed -$38.9K – 192
2026
Q2
$38.9K Buy
+4,860
New +$41.8K ﹤0.01% 140

Other funds holding SPRY

Diadema Partners's SPRY Position: Q3 2026 in Review

Diadema Partners sold out of ARS Pharmaceuticals (SPRY) in Q3 2026, closing a stake of 4,860 shares — an estimated $38.9K sold.

Diadema Partners first reported a position in SPRY in Q2 2026 and held it in 1 quarter. The position peaked at $38.9K in Q2 2026. 185 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

  • Diadema Partners reported no remaining ARS Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Diadema Partners sold 4,860 ARS Pharmaceuticals shares in Q3 2026, an estimated $38.9K.
  • Diadema Partners first reported a position in ARS Pharmaceuticals in Q2 2026 and held it in 1 quarter.
  • Diadema Partners's ARS Pharmaceuticals position peaked at $38.9K in Q2 2026.
  • 185 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on Diadema Partners's 13F filing for Q3 2026, filed 16 Nov 2026.